The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections

Simple item page
dc.contributor.authorMoubarak, Mohamed
dc.contributor.authorKasozi, Keneth Iceland
dc.contributor.authorMatama, Kevin
dc.contributor.authorKairania, Emmanuel
dc.contributor.authorMusenero, Monica
dc.contributor.authorWelburn, Susan Christina
dc.contributor.authorBatiha, Gaber El-Saber
dc.date.accessioned2022-09-14T10:50:48Z
dc.date.available2022-09-14T10:50:48Z
dc.date.issued2021
dc.description.abstractNovel therapies for the treatment of COVID-19 are continuing to emerge as the SARS-Cov-2 pandemic progresses. PCR remains the standard benchmark for initial diagnosis of COVID-19 infection, while advances in immunological profiling are guiding clinical treatment. The SARS-Cov-2 virus has undergone multiple mutations since its emergence in 2019, resulting in changes in virulence that have impacted on disease severity globally. The emergence of more virulent variants of SARS-Cov-2 remains challenging for effective disease control during this pandemic. Major variants identified to date include B.1.1.7, B.1.351; P.1; B.1.617.2; B.1.427; P.2; P.3; B.1.525; and C.37. Globally, large unvaccinated populations increase the risk of more and more variants arising. With successive waves of COVID-19 emerging, strategies that mitigate against community transmission need to be implemented, including increased vaccination coverage. For treatment, convalescent plasma therapy, successfully deployed during recent Ebola outbreaks and for H1N1 influenza, can increase survival rates and improve host responses to viral challenge. Convalescent plasma is rich with cytokines (IL-1β, IL-2, IL-6, IL-17, and IL-8), CCL2, and TNFα, neutralizing antibodies, and clotting factors essential for the management of SARS-CoV-2 infection. Clinical trials can inform and guide treatment policy, leading to mainstream adoption of convalescent therapy. This review examines the limited number of clinical trials published, to date that have deployed this therapy and explores clinical trials in progress for the treatment of COVID-19.en_US
dc.identifier.citationMoubarak, M., Kasozi, K. I., Hetta, H. F., Shaheen, H. M., Rauf, A., Al-Kuraishy, H. M., ... & Batiha, G. E. S. (2021). The rise of SARS-CoV-2 variants and the role of convalescent plasma therapy for management of infections. Life, 11(8), 734.https://doi.org/10.3390/life11080734en_US
dc.identifier.issn2075-1729
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/4727
dc.language.isoenen_US
dc.publisherLifeen_US
dc.subjectcoronavirus; COVID-19 therapy; COVID-19 vaccine; COVID-19 convalescent therapy; SARS-CoV-2 infection; human antibodies; variants of concern; Ebolaen_US
dc.titleThe Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infectionsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections.pdf
Size:
2.07 MB
Format:
Adobe Portable Document Format
Description:
The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences